Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0085 • ACR Convergence 2025
Single Cell RNA-seq Revealed Immune/epithelial Cell Abnormalities Underlying the Pathogenesis of Rheumatoid Arthritis-related Interstitial Lung Disease
Kensuke Suga¹, Amara Seng², Changfu Yao³, Tanyalak Parimon³, Youn Jung Choi², Justyna Fert-Bober⁴, Barry Stripp³, Jon Giles⁵, Peter Chen³ and Nunzio Bottini⁶, ¹Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Beverly Hills, CA, ²Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ³Women's Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Cedars Sinai Medical Center, Los Angeles, CA, ⁶Cedars Sinai Medical Center, Beverly Hills, CA
Background/Purpose: Interstitial lung disease (ILD) is one of the extra-articular manifestations of rheumatoid arthritis (RA) characterized by inflammation and/or fibrosis. Clinically relevant RA-ILD occurs in…
Abstract Number: 0067 • ACR Convergence 2025
Identification of Neutrophil Extracellular Traps in Explanted Human Lungs with Rheumatoid Arthritis-related Interstitial Lung Disease
Amara Seng¹, Kensuke Suga², Diana Tran³, Anvita Singaraju⁴, Tanyalak Parimon⁵, Youn Jung Choi⁶, Justyna Fert-Bober⁷, Jon Giles⁸, Peter Chen⁵ and Nunzio Bottini⁹, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Beverly Hills, CA, ³Cedars Sinai Medical Center, La Cañada Flintridge, CA, ⁴Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Los Angeles, ⁵Women's Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ⁶Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Cedars Sinai Medical Center, Los Angeles, CA, ⁹Cedars Sinai Medical Center, Beverly Hills, CA
Background/Purpose: Symptomatic rheumatoid arthritis-related interstitial lung disease (RA-ILD) is prevalent in about 10% of patients with RA and confers a higher mortality compared with RA…
Abstract Number: 0022 • ACR Convergence 2025
Genome-wide association study identifies novel genetic risk factors for rheumatoid arthritis-associated interstitial lung disease
Austin Wheeler¹, Thomas Riley², Riku Takei³, Joshua Baker², Yangyuna Yang¹, Punyasha Roul⁴, Katherine Wysham⁵, Grant Cannon⁶, Gary Kunkel⁷, Gail Kerr⁸, Dana Ascherman⁹, Paul Monach¹⁰, Andreas Reimold¹¹, Jill Poole¹, Ted Mikuls¹, Tony Merriman¹² and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴UNMC, Omaha, NE, ⁵VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁹University of Pittsburgh, Pittsburgh, PA, ¹⁰VA Boston Healthcare System, Boston, MA, ¹¹Dallas VA Medical Center, Dallas, TX, ¹²University of Alabama at Birmingham, Homewood, AL
Background/Purpose: Interstitial lung disease (ILD) is clinically present in ~10% of individuals with RA. There is recognized overlap between RA-ILD and idiopathic pulmonary fibrosis (IPF)…
Abstract Number: 2640 • ACR Convergence 2025
Effectiveness of Biological and Target-Synthetic Treatment in Patients with Rheumatoid Arthritis and Kidney Dysfunction: A Large Prospective Registry Study
Sho Fukui¹, Hilde Ørbo², Sara Tedeschi¹, Hongshu Guan³, Leslie Harrold⁴, Heather Litman⁵ and Daniel Solomon¹, ¹Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ²Diakonhjemmet Hospital, Oslo, Norway, ³Brigham and Women's Hospital/ Harvard Medical School, Boston, ⁴CorEvitas, Northborough, MA, ⁵Corrona, LLC, Waltham, MA
Background/Purpose: Kidney dysfunction is common in patients with rheumatoid arthritis (RA). However, there has been limited and conflicting evidence on the effectiveness of biologic and…
Abstract Number: 2293 • ACR Convergence 2025
CLN-978, a CD19 x CD3-Directed T Cell Engager, Leads to Rapid and Deep B Cell Depletion In Vitro and In Vivo, Supporting Clinical Development Across Multiple Autoimmune Diseases
Ella Ioffe, Karsten Sauer, Todd Shearer, Jennifer Michaelson, Jeffrey Jones, Yue Zhang, Stephen Wax and Antoine Sreih, Cullinan Therapeutics Inc, Cambridge, MA
Background/Purpose: Treatments depleting CD19-expressing B cells have shown benefit in a range of autoimmune diseases. T cell engagers (TCE) offer off-the-shelf convenience, the predictable pharmacokinetic/pharmacodynamic…
Abstract Number: 2273 • ACR Convergence 2025
Impact of Upadacitinib on Glucocorticoid Reduction in Patients with Moderate-to-Severe RA Who Achieved and Maintained Clinical Remission in the 2-Year UPHOLD Study
FRANK BUTTGEREIT¹, Andrew Ostor², Philip Conaghan³, Ana Romero⁴, Ivan Lagunes⁵, Andrew Garrison⁶, Tianming Gao⁷ and Suzan Attar⁸, ¹Charité University Medicine Berlin, Berlin, Berlin, Germany, ²Australian National University, Canberra, Australia, ³University of Leeds, Leeds, United Kingdom, ⁴AbbVie, Barcelona, Spain, ⁵Abbvie Inc, North Chicago, IL, ⁶AbbVie, USA, North Chicago, IL, ⁷AbbVie, North Chicago, IL, ⁸King Abdulaziz University, Saudi Arabia, Jeddah, Saudi Arabia

Background/Purpose: Glucocorticoids (GCs) are fast-acting drugs used to support csDMARD therapy for RA, but should be used sparingly and for short periods.1 Upadacitinib, an oral…
Abstract Number: 2257 • ACR Convergence 2025
Impact of Family History of RA in Patients Evaluated for Arthralgia: A Comprehensive Analysis of the Reuma-check Cohort
Rodrigo García Salinas¹, Juan Arguello², Santiago Ruta³, Ronald Perez² and Sebastian Magri⁴, ¹Hospital Italiano La Plata, La Plata, Argentina, ²Hospital Italiano de La Plata, La Plata, Argentina, ³Hospital San Martin de La Plata, La Plata, Argentina, ⁴Hospital Italiano La Plata, Melchor Romero, Argentina
Background/Purpose: First-degree family history of rheumatoid arthritis (RA) is a relevant factor in genetic predisposition and early diagnosis of the disease. Objectives: 1)Estimate the frequency…
Abstract Number: 2239 • ACR Convergence 2025
Increased Cardiovascular Morbidity in Patients with Rheumatoid Arthritis and Type 2 Diabetes: A Large-Scale Electronic Health Record Analysis
Godbless Ajenaghughrure¹, Sila Mateo Faxas², Gurjot Singh³, Nirys Mateo Faxas⁴, Kim Nguyen³, Nicole Tejeda⁵ and Kimberly Ramirez Bonetti⁶, ¹Trihealth Good Samaritan Hospital, Cincinnati, OH, ²Good Samaritan Hospital, Cincinnati, OH, ³Trihealth Good Samaritan Hospital, Cincinnati, ⁴Independent Author, Santo Domingo, Dominican Republic, ⁵Independent Author, Cincinnati, ⁶Independent Author, cincinnati, OH
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased cardiovascular risk, but the additional impact of comorbid type 2 diabetes mellitus (T2DM) on cardiovascular outcomes in…
Abstract Number: 2207 • ACR Convergence 2025
Menopause Experiences of Veterans from Minoritized Populations with Rheumatoid Arthritis
Catherine Sims¹, Yujung Choi², Abigail Shapiro³, Jennifer Gierisch¹, Elizabeth Strawbridge², Teresa Howard², Ankoor Shah¹ and Karen Goldstein¹, ¹VA Durham Healthcare System, Duke University, Durham, ²VA Durham Healthcare System, Durham, ³VA Durham Healthcare System, Cleveland
Background/Purpose: There is a significant gap in understanding the reproductive health experiences of women Veterans with rheumatoid arthritis (RA). This study explores their experiences with…
Abstract Number: 1946 • ACR Convergence 2025
Quantitative Imaging Analysis of Chest Computed Tomography in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Emily Anthone¹, Emily Wan², Aimee Schreiner¹, Katherine Wysham³, Gary Kunkel⁴, Grant Cannon⁵, Andreas Reimold⁶, John Richards⁷, Dana Ascherman⁸, Gail Kerr⁹, Paul Monach¹⁰, Halie Frideres¹¹, Punyasha Roul¹², Scott Matson¹³, Joshua Baker¹⁴, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²VA Boston, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁵University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁶Dallas VA Medical Center, Dallas, TX, ⁷Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ⁸University of Pittsburgh, Pittsburgh, PA, ⁹Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹⁰VA Boston Healthcare System, Boston, MA, ¹¹UNMC Department of Rheumatology, Omaha, NE, ¹²UNMC, Omaha, NE, ¹³University of Kansas, Kansas City, MO, ¹⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Interstitial lung disease (ILD) frequently complicates the disease course in RA. While forced vital capacity (FVC) from pulmonary function tests (PFTs) is the most…
Abstract Number: 1884 • ACR Convergence 2025
The Importance of Adherence to Dietary Recommendations for Rheumatoid Arthritis Risk May Be Greater in Younger Individuals – Results from a Nested Case-Control Study
Rebecka Bäcklund¹, Ulf Bergström¹, Michele Compagno¹, Linnea arvidsson², Emil Rydell³, Emily Sonestedt¹ and Carl Turesson³, ¹Lund University, Malmö, Sweden, ²Lund University, Malmö, ³Lund University, Malmö, Sweden
Background/Purpose: Healthy eating habits might prevent the development of rheumatoid arthritis (RA). The impact of such lifestyle factors on the risk of RA may differ…
Abstract Number: 1701 • ACR Convergence 2025
Gene Editing of HLA-Class II DRB1*04:01 at Position 82 Abrogates Binding of Citrullinated Arthritogenic Peptides and Collagen
Vibha Jha¹, Brian Freed², Niyun Jin¹, Manjula Miglani¹ and Christina Roark², ¹University of Colorado, Aurora, CO, ²Clinimmune Labs Immunology, School of Medicine, Aurora, CO
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease with a strong genetic association to Class II HLA-DRB1*04:01. Presentation of arthritogenic peptides bound to DRB1*04:01…
Abstract Number: 1646 • ACR Convergence 2025
The Obesity Paradox in Rheumatoid Arthritis: A Propensity-Matched Analysis of Mortality and Cardiovascular Outcomes
Queeneth Edwards¹, Chukwuemelie Okeke², Justin Riley³, Ufuoma Mamoh⁴ and Chekwube Obianyo⁵, ¹Georgia Southern University, Statesboro, GA, ²Maimonides Medical Center, Brooklyn, NY, ³Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, ⁴Medstar Health Georgetown University Internal Medicine Residency Program, Baltimore, MD, ⁵Georgia Southern University, statesboro
Background/Purpose: Obesity is traditionally associated with increased morbidity and mortality in the general population. However, in chronic inflammatory conditions like rheumatoid arthritis (RA), an "obesity…
Abstract Number: 1361 • ACR Convergence 2025
Efficacy of Telitacicept in the treatment of Connective tissue disease-associated interstitial lung disease: A Potential therapeutic option
Mingfang Sun¹, Xue Chen², Ying Zhou², Yanlong Yang², Fei Xiao² and huanzi dai², ¹Daping Hospital, chongqing, China (People's Republic), ²Daping Hospital & Research Institute of Surgery, Army Medical University, Chongqing, PR China., Chongqing, China (People's Republic)
Background/Purpose: Connective tissue disease-associated interstitial lung disease(CTD-ILD) represents a significant cause of mortality among patients. Presently, research on treatment options for CTD-ILD is limited, with…
Abstract Number: 1344 • ACR Convergence 2025
Exploring the Factors Associated with the Discontinuation of Tofacitinib in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
yao fan fang¹, Ping-Han Tsai² and yen Fu CHEN³, ¹Chang Gung memorial hopspital, Linkou, Taipei, New Taipei, Taiwan (Republic of China), ²Chang Gung memorial hospital, linkou, Taipei, Taiwan (Republic of China), ³Chang Gung memoriial hospital linkou, taipei, Taiwan (Republic of China)
Background/Purpose: Tofacitinib is the first oral targeted synthetic disease-modify anti-rheumatic drug for patients with moderate to severe rheumatoid arthritis 1. This study aimed to identify…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].